PSCA (14-22)

Prostate Stem Cell Antigen; PSCA

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.

CAT No: ta-561

Synonyms/Alias:Prostate Stem Cell Antigen (14-22); PSCA (14-22)

Custom Peptide Synthesis
cGMP Peptide
  • Registration of APIs
  • CMC information required for an IND
  • IND and NDA support
  • Drug master files (DMF) filing
Sequence
ALQPGTALL
Areas of Interest
Antigen-presenting Cells; Cancer Research

PSCA (14-22) is a synthetic peptide fragment derived from the prostate stem cell antigen (PSCA), a glycosylphosphatidylinositol (GPI)-anchored cell surface protein implicated in a variety of cellular processes and frequently studied in the context of prostate and other epithelial cancers. The 14-22 region of PSCA encompasses a specific amino acid sequence that is of particular interest for its antigenic properties and functional relevance in cell signaling and immune recognition. As a research-grade peptide, PSCA (14-22) serves as a valuable tool for probing the molecular mechanisms underlying PSCA-mediated pathways, evaluating immunogenic epitopes, and supporting the development of novel diagnostic and investigative approaches in cancer biology and cell surface antigen research.

Epitope mapping: Researchers utilize PSCA (14-22) in epitope mapping studies to delineate the precise regions of the PSCA protein that are recognized by antibodies or immune cells. By employing this defined peptide fragment, investigators can systematically characterize the immunodominant domains within the PSCA sequence, facilitating the identification of key antigenic determinants. Such studies are essential for the rational design of antibody-based detection reagents, immunoassays, and for advancing the understanding of antigen-antibody interactions relevant to prostate cancer and related malignancies.

Immunological assays: The peptide is frequently used as a target antigen in enzyme-linked immunosorbent assays (ELISA), T-cell activation assays, and other in vitro immunological platforms. Its defined sequence enables the assessment of humoral and cellular immune responses against PSCA, supporting the evaluation of immune recognition in preclinical models or patient-derived samples. Utilizing this fragment allows for the selective investigation of immune reactivity to a specific region of the PSCA protein, providing insight into the immunogenic landscape of cancer-associated antigens.

Peptide-based screening: PSCA (14-22) is an important component in peptide library screening and binding studies aimed at identifying novel ligands, antibodies, or small molecules that interact with the PSCA protein. By presenting this discrete sequence, researchers can perform high-throughput screenings to discover candidates with high specificity and affinity for the PSCA epitope, informing the development of targeted research reagents and supporting structure-activity relationship analyses.

Cellular signaling research: The defined PSCA (14-22) sequence is employed in mechanistic studies to investigate its potential involvement in cell surface signaling, receptor-ligand interactions, and downstream cellular responses. By introducing the peptide into cell culture models or biochemical assays, scientists can probe its capacity to modulate or mimic native PSCA functions, thereby elucidating the role of this region in cellular communication, adhesion, or signaling cascades relevant to epithelial cell biology.

Antibody validation: The peptide fragment serves as a reference standard for the validation and characterization of anti-PSCA antibodies. By providing a well-defined target, PSCA (14-22) allows researchers to assess antibody specificity, affinity, and cross-reactivity in various immunodetection techniques, such as Western blotting, immunohistochemistry, or flow cytometry. This application is critical for ensuring the reliability and reproducibility of antibody-based tools in both basic research and translational studies involving PSCA expression and function.

Source#
Homo sapiens (human)
Epitope
14-22
Restricting HLA
HLA-A2
References
Anna-K. Thomas-Kaskel; Cancer Therapy 2006

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Featured Services
Peptide Nucleic Acids SynthesisPeptide Synthesis ServicesCustom Conjugation ServicePeptide Modification ServicesEpitope Mapping ServicesPeptide CDMOPeptide Analysis ServicescGMP Peptide Service
Hot Products
About us

Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.

From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.

Our Customers